Cara Cassino spent a year advising Oligomerix from the boardroom. Now she’s running the company as its lead drug enters human trials.
Dr Cara Cassino joined the Oligomerix board in July 2025. Thirteen months later, she’s the one running meetings, not attending them.
The Bronx-based biotech announced 31 August that Cassino will serve as interim President and CEO, stepping into the role at a moment the company describes as a genuine inflection point. Oligomerix has spent years as a discovery-stage operation, running experiments, publishing data, building a case for its lead molecule. That phase is over. The company’s tau-targeting compound, OLX-07010, just cleared its first human safety trial, and clinical-stage biotechs answer to a different clock: trial enrollment, regulatory meetings, burn rate. Cassino has run that gauntlet before [1].
Two decades at Boehringer Ingelheim and Pfizer. A hand in Spiriva’s success, the respiratory drug that became one of Pfizer’s steadiest sellers. Senior clinical development roles at Forest Laboratories during a stretch the company later credited with reshaping its pipeline. Then the jump to biotech leadership itself, chief medical officer, EVP of R&D and eventually interim co-CEO at ContraFect, where she helped secure an $86 million government grant from BARDA, the agency that funds biodefense and pandemic preparedness research. Along the way, she’s been party to biotech financings totaling more than $190 million.
None of that guarantees OLX-07010 works, but it does mean Oligomerix now has someone at the helm who has personally shepherded molecules through the exact transition the company is facing.
What the drug is chasing
Tau is a protein that, under normal circumstances, helps stabilize the internal scaffolding of brain cells. In Alzheimer’s disease, tau molecules start sticking to each other instead, forming tangles that correlate closely with cognitive decline. OLX-07010 is designed to interrupt that clumping process before it starts, an approach distinct from the amyloid-targeting antibodies, like lecanemab, that dominate current Alzheimer’s treatment. Where those drugs require infusion or injection, Oligomerix is chasing something patients could simply swallow once a day.
In animal studies, the compound blocked tau accumulation across multiple models. In its Phase 1a trial, it produced a favorable safety profile in healthy volunteers, clearing a hurdle that has ended plenty of Alzheimer’s candidates before they ever reached a patient with the disease.
The people making the call
Bill Caple, Oligomerix’s chairman, didn’t hedge in the announcement.
“We are very pleased to welcome a leader of this caliber, with a depth of clinical development experience,” he said. “Dr Cassino joins Oligomerix as Interim President and CEO at a critical time, as the company evolves from a discovery-focused biotech to a clinical-stage drug development organization. Having successfully completed a Phase 1a study of our lead compound, Dr Cassino brings tremendous insight, experience and know-how as the company advances OLX-07010 into the next stages of the clinical development.”
Cassino’s own statement leaned less on résumé, more on mission.
“I am excited to join Oligomerix as Interim President & CEO and look forward to working with the team to advance OLX-07010 as a novel oral therapeutic with the potential to improve the lives of patients with Alzheimer’s disease and other progressive neurodegenerative diseases,” she said.
Boards don’t always reach for a sitting director when they need a new chief executive, but it happens often enough when speed and trust matter more than a lengthy search. Cassino already knew the science. She already knew the team. She didn’t need an onboarding period.
Why a pill, not just a protein, matters for aging brains
Oligomerix isn’t only chasing Alzheimer’s. Its research also targets progressive supranuclear palsy and frontotemporal dementia, rarer neurodegenerative diseases that share tau’s tendency to misfold and clump. The company operates out of the Ullmann Research Center for Health Sciences at Albert Einstein College of Medicine, embedded in an academic environment built around exactly this kind of protein biology.
There’s a reason this matters beyond the lab. Longevity science tends to get discussed in terms of lifespan, extra years tacked onto the end of a life. However, tau pathology builds for years, sometimes decades, before memory loss becomes noticeable, quietly eroding the brain that has to carry a person through whatever extra years modern medicine buys them. A drug’s delivery method isn’t a footnote to that story, either. A once-daily pill is something a patient can realistically stay on for years. An infusion regimen, less so, and adherence gaps are exactly where promising therapies quietly fail in the real world.
OLX-07010 has cleared one small trial. Plenty of Alzheimer’s drugs have made it this far and stalled later, sometimes badly. What’s changed is who’s now accountable for getting it further, and whether Cassino’s fourth or fifth trip through this particular gauntlet ends differently than the last one.
